Myostatin — research review 2

...and this idea of myostatin as a brake on muscle growth is fascinating. For years, we’ve heard the hype about inhibiting it to build massive muscle, but what does the human evidence actually say?

That's the key, isn't it? Moving from theoretical pathways to actual human benefit. We’ve seen a lot of preclinical work, but in humans, the story is still developing, and frankly, a bit more nuanced.

Right. Because you can see an effect in a petri dish or a mouse, but that doesn't always translate. Are there any clinical trials in humans looking at myostatin inhibitors?

Yes, there have been. A notable one, published in Neurology in 2017, looked at a myostatin inhibitor in patients with Duchenne muscular dystrophy. The primary outcome measure was muscle function.

And what did that trial show?

Interestingly, it didn't meet its primary endpoint. They observed no statistically significant improvement in muscle function compared to placebo. It was a null result for that specific population and outcome.

Which is crucial information, even if it’s not what people hoped for. It tells us something important about the molecule’s effect in a human disease context. Does that mean myostatin inhibition is a dead end for longevity or general muscle health?

Not necessarily a dead end, but it highlights the complexity. For healthy individuals, or even in other sarcopenic populations, the evidence is even thinner, often speculative. We just don't have robust human trials showing a clear, significant benefit for increasing muscle mass or strength in healthy aging, for example. What's still unknown far outweighs what's proven in humans outside of very specific, severe muscle wasting conditions, and even there, the results are mixed. We need more data.